Fundamental Analysis of FINCH THERAPEUTICS GROUP INC(NASDAQ:FNCH) stock

Fundamental Rating

FNCH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. While FNCH seems to be doing ok healthwise, there are quite some concerns on its profitability. FNCH has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

FNCH had negative earnings in the past year.

In the past year FNCH has reported a negative cash flow from operations.

In the past 5 years FNCH always reported negative net income.

FNCH had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of FNCH (-135.01%) is worse than 84.62% of its industry peers.

FNCH has a Return On Equity of -326.67%. This is in the lower half of the industry: FNCH underperforms 76.41% of its industry peers.

		Industry Rank	Sector Rank
ROA	-135.01%
ROE	-326.67%
ROIC	N/A

ROA(3y)-77.06%

ROA(5y)-55%

ROE(3y)-158.4%

ROE(5y)-105.73%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FNCH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FNCH does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, FNCH has more shares outstanding

FNCH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

FNCH has an Altman-Z score of -10.34. This is a bad value and indicates that FNCH is not financially healthy and even has some risk of bankruptcy.

FNCH's Altman-Z score of -10.34 is on the low side compared to the rest of the industry. FNCH is outperformed by 77.78% of its industry peers.

FNCH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.34

ROIC/WACCN/A

WACC4.51%

2.3 Liquidity

A Current Ratio of 6.33 indicates that FNCH has no problem at all paying its short term obligations.

FNCH has a better Current ratio (6.33) than 64.10% of its industry peers.

FNCH has a Quick Ratio of 6.33. This indicates that FNCH is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 6.33, FNCH is doing good in the industry, outperforming 64.44% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.33
Quick Ratio	6.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.24% over the past year.

Looking at the last year, FNCH shows a very negative growth in Revenue. The Revenue has decreased by -87.21% in the last year.

FNCH shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -75.98% yearly.

EPS 1Y (TTM)35.24%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q88.79%

Revenue 1Y (TTM)-87.21%

Revenue growth 3Y-75.98%

Revenue growth 5YN/A

Revenue growth Q2Q-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

Based on estimates for the next years, FNCH will show a very strong growth in Revenue. The Revenue will grow by 507.50% on average per year.

EPS Next Y45.96%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y2874.9%

Revenue Next 3Y1411.62%

Revenue Next 5Y507.5%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FNCH. In the last year negative earnings were reported.

Also next year FNCH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FNCH does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FINCH THERAPEUTICS GROUP INC

NASDAQ:FNCH (5/3/2024, 7:00:00 PM)

2.3

-0.19 (-7.63%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.70M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-135.01%
ROE	-326.67%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.33
Quick Ratio	6.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)35.24%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y45.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-87.21%

Revenue growth 3Y-75.98%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

FINCH THERAPEUTICS GROUP INC (FNCH)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens